Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$4.15B |
| 2 |
NVIDIA
NVDA
|
+$4.1B |
| 3 |
Starbucks
SBUX
|
+$3.07B |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$1.91B |
| 5 |
UnitedHealth
UNH
|
+$1.46B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$5.5B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$3.28B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.66B |
| 4 |
GE Aerospace
GE
|
+$1.57B |
| 5 |
PNC Financial Services
PNC
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.59% |
| 2 | Healthcare | 17.77% |
| 3 | Consumer Discretionary | 12.89% |
| 4 | Industrials | 11.65% |
| 5 | Financials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Lamb Weston
LW
$7.38B
| $71.7M | 0.02% |
1,345,251
-4,988,287
| -79% | -$283M |
|
327
CNX Resources
CNX
$5.25B
| $71.6M | 0.02% |
2,275,000
+825,000
| +57% | +$24.9M |
|
328
Essent Group
ESNT
$6.18B
| $70.3M | 0.02% |
1,218,372
+1,213,872
| +26,975% | +$68.8M |
|
329
Bristol-Myers Squibb
BMY
$131B
| $70.1M | 0.02% |
1,150,000
| – | – |
|
330
First Solar
FSLR
$24.1B
| $69.7M | 0.02% |
551,423
-1,238,091
| -69% | -$193M |
|
331
Acushnet Holdings
GOLF
$5.29B
| $69.5M | 0.02% |
+1,011,742
| New | +$68.7M |
|
|
REVG
332
DELISTED
REV Group
REVG
| $69.3M | 0.02% |
2,192,398
+603,754
| +38% | +$19.6M |
|
333
GSK
GSK
$101B
| $68.3M | 0.01% |
1,762,158
+2,950
| +0.2% | +$108K |
|
334
State Street
STT
$52.6B
| $68M | 0.01% |
760,000
-154,141
| -17% | -$14.7M |
|
335
Lowe's Companies
LOW
$122B
| $67.6M | 0.01% |
+289,920
| New | +$71.3M |
|
336
MongoDB
MDB
$36.8B
| $67M | 0.01% |
381,705
-170,835
| -31% | -$41.6M |
|
337
Deere & Co
DE
$167B
| $65.4M | 0.01% |
+139,378
| New | +$65.2M |
|
338
Encompass Health
EHC
$12.3B
| $65.2M | 0.01% |
644,233
-136,696
| -18% | -$13.3M |
|
339
Denali Therapeutics
DNLI
$4.05B
| $64.8M | 0.01% |
4,765,137
-712,074
| -13% | -$13.6M |
|
340
Extra Space Storage
EXR
$31.4B
| $63.1M | 0.01% |
425,215
+782
| +0.2% | +$119K |
|
341
Lumentum
LITE
$83.5B
| $61.8M | 0.01% |
991,310
+486,073
| +96% | +$37.4M |
|
342
Willis Towers Watson
WTW
$31.5B
| $61.7M | 0.01% |
182,572
-243,654
| -57% | -$79.4M |
|
343
Pinnacle Financial Partners Inc
PNFP
$16.3B
| $60.8M | 0.01% |
573,150
-986,648
| -63% | -$113M |
|
344
International Flavors & Fragrances
IFF
$21.5B
| $58.5M | 0.01% |
753,785
| – | – |
|
345
Analog Devices
ADI
$189B
| $57.2M | 0.01% |
283,558
+115,043
| +68% | +$24.9M |
|
346
Sempra
SRE
$56.8B
| $57.1M | 0.01% |
800,000
-197,194
| -20% | -$15.4M |
|
347
AstraZeneca
AZN
$244B
| $56.7M | 0.01% |
385,384
+1,520
| +0.4% | +$220K |
|
348
Comfort Systems
FIX
$60.9B
| $56.6M | 0.01% |
175,660
-76,411
| -30% | -$30.8M |
|
349
Shell
SHEL
$247B
| $56.3M | 0.01% |
767,903
+2,253
| +0.3% | +$152K |
|
350
Nutrien
NTR
$32B
| $55.9M | 0.01% |
1,126,228
+2,050
| +0.2% | +$105K |
|
Similar funds
Capital Research Global Investors's Q1 2025 Portfolio in Review
As of Q1 2025, Capital Research Global Investors held 477 positions worth $460B, down 5.4% from $486B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Capital Research Global Investors's Q1 2025 filing shows 39 new, 191 increased, 187 reduced and 21 closed positions. Its largest new stake was Charter Communications: 1,626,990 shares worth $600M. The largest sale was Apple, an estimated $5.5B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Capital Research Global Investors's largest Q1 2025 buy was Charter Communications: 1,626,990 shares worth $600M.
- Capital Research Global Investors added most to Eli Lilly in Q1 2025, an estimated $4.15B increase.
- Capital Research Global Investors's biggest Q1 2025 reduction was Apple, cutting an estimated $5.5B.
- Capital Research Global Investors fully exited East-West Bancorp in Q1 2025, selling an estimated $410M.
- Capital Research Global Investors's ten largest holdings make up 31% of its $460B portfolio in Q1 2025.
- Capital Research Global Investors opened 39 new positions and closed 21 in Q1 2025.
- Capital Research Global Investors's portfolio value fell 5.4% quarter-over-quarter to $460B.
Based on Capital Research Global Investors's 13F filing for Q1 2025, filed 12 May 2025.